Endocannabinoids (eCBs) are endogenous lipid mediators involved in a variety of physiological, pharmacological, and pathological processes. While activation of the eCB system primarily induces inhibitory effects on both GABAergic and glutamatergic synaptic transmission and plasticity through acting on presynaptically expressed CB1 receptors in the brain, accumulated information suggests that eCB signaling is also capable of facilitating or potentiating excitatory synaptic transmission in the hippocampus. Recent studies show that a long-lasting potentiation of excitatory synaptic transmission at Schaffer collateral (SC)-CA1 synapses is induced by spatiotemporally primed inputs, accompanying with a long-term depression of inhibitory synaptic transmission (I-LTD) in hippocampal CA1 pyramidal neurons. This input timing–dependent long-lasting synaptic potentiation at SC-CA1 synapses is mediated by 2-arachidonoylglycerol (2-AG) signaling triggered by activation of postsynaptic N-methyl-d-aspartate receptors, group I metabotropic glutamate receptors (mGluRs), and a concurrent rise in intracellular Ca2+. Emerging evidence now also indicates that 2-AG is an important signaling mediator keeping brain homeostasis by exerting its anti-inflammatory and neuroprotective effects in response to harmful insults through CB1/2 receptor-dependent and/or -independent mechanisms. Activation of the nuclear receptor protein peroxisome proliferator-activated receptor-γ apparently is one of the important mechanisms in resolving neuroinflammation and protecting neurons produced by 2-AG signaling. Thus, the information summarized in this review suggests that the role of eCB signaling in maintaining integrity of brain function is greater than what we thought previously.
AdamsIBMartinBR. 1996. Cannabis: pharmacology and toxicology in animals and humans. Addiction91:1585–614.
2.
AlgerBEPitlerTA. 1995. Retrograde signaling at GABAA-receptor synapses in the mammalian CNS. Trends Neurosci18:333–40.
3.
AlgerBE. 2002. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol68:247–86.
4.
AlgerBE. 2009. Endocannabinoid signaling in neural plasticity. Curr Top Behav Neurosci1:141–72.
5.
AmaralDGWitterMP. 1989. The three-dimensional organization of the hippocampal formation: a review of anatomical data. Neuroscience31:571–91.
6.
AndersenPBlissTVSkredeKK. 1971. Lamellar organization of hippocampal pathways. Exp Brain Res13:222–38.
7.
Arevalo-MartinAGarcia-OvejeroDMolina-HolgadoE. 2010. The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury. Neurobiol Dis38:304–12.
8.
AzadSCMonoryKMarsicanoGCravattBFLutzBZieglgansbergerW, and others. 2004. Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci24:9953–61.
9.
BasuJSrinivasKVCheungSKTaniguchiHHuangZJSiegelbaumSA. 2013. A cortico-hippocampal learning rule shapes inhibitory microcircuit activity to enhance hippocampal information flow. Neuron79:1208–21.
10.
BenderVABenderKJBrasierDJFeldmanDE. 2006. Two coincidence detectors for spike timing-dependent plasticity in somatosensory cortex. J Neurosci26:4166–77.
11.
BenitoCNunezETolonRMCarrierEJRabanoAHillardCJ, and others. 2003. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J Neurosci23:11136–41.
12.
BensingerSTTontonozP. 2008. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature454:470–7.
13.
BisognoTDi MarzoV. 2010. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets9:564–73.
14.
BlankmanJLSimonGMCravattBF. 2007. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol14: 1347–56.
15.
BlennowKHardyJZetterbergH. 2012. The neuropathology and neurobiology of traumatic brain injury. Neuron. 76:886–99.
16.
BlissTVGardner-MedwinAR. 1973. Long-lasting potentiation of synaptic transmission in the dentate area of the unanaestetized rabbit following stimulation of the perforant path. J Physiol232:357–74.
17.
BlissTVLomoT. 1973. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol232:331–56.
18.
BrightJJKanakasabaiSChearwaeWChakrabortyS. 2008. PPAR regulation of inflammatory signaling in CNS diseases. PPAR Res2008:1–12.
19.
BrunVHLeutgebSWuHQSchwarczRWitterMPMoserEI, and others. 2008. Impaired spatial representation in CA1 after lesion of direct input from entorhinal cortex. Neuron57:290–302.
20.
CabralGARabornESGriffinLDennisJMarciano-CabralF. 2008. CB2 receptors in the brain: role in central immune function. Br J Pharmacol153:240–51.
21.
CarlsonGWangYAlgerBE. 2002. Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat Neurosci5:723–4.
22.
CastilloPEYountsTJChavezAEHashimotodaniY. 2012. Endocannabinoid signaling and synaptic function. Neuron76:70–81.
23.
CentonzeDFinazzi-AgròABernardiGMaccarroneM. 2007. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci28: 180–7.
24.
ChenRZhangJWuYWangDFengGTangYP, and others. 2012. Monoacylglycerol lipase is a therapeutic target for Alzheimer’s disease. Cell Rep2:1329–39.
25.
ChenRZhangJFanNTengZWuYYangH, and others. 2013. Δ9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling. Cell155:1554–65.
26.
ChenXZhangJChenC. 2011. Endocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults. Neuroscience178:159–68.
27.
ChevaleyreVCastilloPE. 2003. Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron38:461–72.
28.
ChevaleyreVCastilloPE. 2004. Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron43:871–81.
29.
ChevaleyreVTakahashiKACastilloPE. 2006. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci29:37–76.
30.
ClaiborneBJAmaralDGCowanWM. 1986. A light and electron microscopic analysis of the mossy fibers of the rat dentate gyrus. J Comp Neurol246:435–58.
31.
ColbertCMLevyWB. 1993. Long-term potentiation of perforant path synapses in hippocampal CA1 in vitro. Brain Res606:87–91.
32.
CravattBFGiangDKMayfieldSPBogerDLLernerRAGilulaNB. 1996. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature384:83–7.
33.
DanYPooMM. 2004. Spike timing-dependent plasticity of neural circuits. Neuron44:23–30.
34.
DardiotisEKaranikasVPaterakisK. 2012. Traumatic brain injury and inflammation: emerging role of innate and adaptive immunity. In: AgrawalA, editor. Brain injury: pathogenesis, monitoring, recovery and management. Rijeka, Croatia: InTech. p 23–38.
35.
DaynesRAJonesDC. 2002. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol2:748–59.
36.
DekoskySTBlennowKIkonomovicMDGandyS. 2013. Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol9:192–200.
37.
DevaneWAHanusLBreuerAPertweeRGStevensonLAGriffinG, and others. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science258:1946–9.
38.
DianaMAMartyA. 2004. Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol142:9–19.
39.
Di MarzoVHillMPBisognoTCrossmanARBrotchieJM. 2000. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease. FASEB J14:1432–8.
40.
DinhTPCarpenterDLeslieFMFreundTFKatonaISensiSLKathuriaSPiomelliD. 2002. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A99:10819–24.
41.
DinhTPKathuriaSPiomelliD. 2004. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol66:1260–4.
42.
DrewPDXuJStorerPDChavisJARackeMK. 2006. Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Int49:183–9.
43.
DuHChenXZhangJChenC. 2011. Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-γ. Br J Pharmacol163:1533–49.
44.
DudmanJTTsayDSiegelbaumSA. 2007. A role for synaptic inputs at distal dendrites: instructive signals for hippocampal long-term plasticity. Neuron56:866–79.
45.
EichenbaumH. 2000. A cortical-hippocampal system for declarative memory. Nat Rev Neurosci1:41–50.
46.
EljaschewitschEWittingAMawrinCLeeTSchmidtPMWolfS, and others. 2006. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron49:67–79.
47.
FreundTFKatonaIPiomelliD. 2003. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev83:1017–66.
48.
GaliegueSMarySMarchandJDussossoyDCarriereDCarayonP, and others. 1995. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem232:54–61.
49.
GaoYVasilyevDVGoncalvesMBHowellFVHobbsCReisenbergM, and others. 2010. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci30:2017–24.
50.
GaoniYMechoulamR. 1964. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 86:1646–7.
51.
GerdemanGLRonesiJLovingerDM. 2002. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci5:446–51.
52.
GerrowKTrillerA. 2010. Synaptic stability and plasticity in a floating world. Curr Opin Neurobiol20:631–9.
53.
GulyasAICravattBFBraceyMHDinhTPPiomelliDBosciaF, and others. 2004. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci20:441–58.
54.
HanusLOMechoulamR. 2010. Novel natural and synthetic ligands of the endocannabinoid system. Curr Med Chem17:1341–59.
55.
HashimotodaniYOhno-ShosakuTKanoM. 2007. Endocannabinoids and synaptic function in the CNS. Neuroscientist13:127–37.
56.
HasselmoMESchnellE. 1994. Laminar selectivity of the cholinergic suppression of synaptic transmission in rat hippocampal region CA1: computational modeling and brain slice physiology. J Neurosci14:3898–914.
57.
HeinAMO’BanionMK. 2009. Neuroinflammation and memory: the role of prostaglandins. Mol Neurobiol40:15–32.
58.
HeinbockelTBragerDHReichCGZhaoJMuralidharanSAlgerBE, and others. 2005. Endocannabinoid signaling dynamics probed with optical tools. J Neurosci25:9449-9459.
59.
HerkenhamMLynnABJohnsonMRMelvinLSDe CostaBRRiceKC. 1991. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci11:563–83.
60.
HerkenhamMLynnABLittleMDJohnsonMRMelvinLSDe CostaBR, and others. 1990. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A87:1932–6.
61.
HowlettACBidaut-RussellMDevaneWAMelvinLSJohnsonMRHerkenhamM. 1990. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci13:420–3.
62.
IshizukaNWeberJAmaralDG. 1990. Organization of intrahippocampal projections originating from CA3 pyramidal cells in the rat. J Comp Neurol295:580–623.
63.
ItoM. 2001. Cerebellar long-term depression: characterization, signal transduction, and functional roles. Physiol Rev81:1143–95.
64.
IzumiYZorumskiCF. 2008. Direct cortical inputs erase long-term potentiation at Schaffer collateral synapses. J Neurosci28:9557–63.
65.
JiangQHenekaMLandrethGE. 2008. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer’s disease: therapeutic implications. CNS Drugs22:1–14.
66.
JordanBD. 2013. The clinical spectrum of sport-related traumatic brain injury. Nat Rev Neurol9:222–30.
67.
JungKMMangieriRStapletonCKimJFegleyDWallaceM, and others. 2005. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol68:1196–202.
68.
KanoMOhno-ShosakuTHashimotodaniYUchigashimaMWatanabeM. 2009. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev89:309–80.
69.
KimJAlgerBE. 2004. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci7:697–8.
70.
KimJIsokawaMLedentCAlgerBE. 2002. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci22:10182–91.
71.
KreitzerACMalenkaRC. 2005. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci25:10537–45.
72.
KreitzerACMalenkaRC. 2007. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease models. Nature445:643–7.
73.
KreitzerACRegehrWG. 2001. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron29:717–27.
74.
KummerMPHenekaMT. 2008. PPARs in Alzheimer’s disease. PPAR Res2008:1–8.
75.
LafourcadeMElezgaraiIMatoSBakiriYGrandesPManzoniOJ. 2007. Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One2:e709.
76.
LakisNCoronaRJToshkeziGChinLS. 2013. Chronic traumatic encephalopathy—neuropathology in athletes and war veterans. Neurol Res35:290–9.
77.
Lastres-BeckerICebeiraMde CeballosMLZengBYJennerPRamosJA, and others. 2001. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson’s syndrome and of MPTP-treated marmosets. Eur J Neurosci14:1827–32.
78.
LenmanAFowlerCJ. 2007. Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system. Br J Pharmacol151:1343–51.
79.
LiuJWangLHarvey-WhiteJOsei-HyiamanDRazdanRGongQ, and others. 2006. A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A103:13345–50.
80.
LlanoILerescheNMartyA. 1991. Calcium entry increases the sensitivity of cerebellar Purkinje cells to applied GABA and decreases inhibitory synaptic currents. Neuron6:565–74.
81.
LongJZNormuraDKCravattBF. 2009a. Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol16:744–53.
82.
LongJZLiWBookerLBurstonJJKinseySGSchlosburgJE, and others. 2009b. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol5:37–44.
83.
Luna-MedinaRCortes-CanteliMAlonsoMSantosAMartínezAPerez-CastilloA. 2005. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferatoractivated receptor γ activation. J Biol Chem280:21453–62.
84.
MakaraJKMorMFegleyDSzaboSIKathuriaSAstaritaG, and others. 2005. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci8:1139–41.
85.
MarsicanoGGoodenoughSMonoryKHermannHEderMCannichA, and others. 2003. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science302:84–8.
86.
MarsicanoGWotjakCTAzadSCBisognoTRammesGCascioMG, and others. 2002. The endogenous cannabinoid system controls extinction of aversive memories. Nature418:530–4.
87.
MatoSLafourcadeMRobbeDBakiriYManzoniOJ. 2008. Role of the cyclic-AMP/PKA cascade and of P/Q-type Ca++ channels in endocannabinoid-mediated long-term depression in the nucleus accumbens. Neuropharmacology54:87–94.
88.
MatsudaLALolaitSJBrownsteinMJYoungACBonnerTI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature346:561–4.
89.
McKeeACSteinTDNowinskiCJSternRADaneshvarDHAlvarezVE, and others. 2013. The spectrum of disease in chronic traumatic encephalopathy. Brain136:43–64.
90.
MechoulamRBen-ShabatSHanusLLigumskyMKaminskiNESchatzAR, and others. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol50:83–90.
91.
MorganNHStanfordIMWoodhallGL. 2009. Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology57:356–68.
92.
MulderJZilberterMPasquaréSJAlpárASchulteGFerreiraSG, and others. 2011. Molecular reorganization of endocannabinoid signalling in Alzheimer’s disease. Brain134:1041–60.
93.
MulvihillMMNomuraDK. 2013. Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci92:492–7.
94.
MunroSThomasKLAbu-ShaarM. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature365:61–5.
95.
NecelaBMSuWThomsonEA. 2008. Toll-like receptor 4 mediates cross-talk between peroxisom proliferator-activated receptor γ and nuclear factor-κB in macrophages. Immunol125:344–58.
96.
NolanMFMalleretGDudmanJTBuhlDLSantoroBGibbsE, and others. 2004. A behavioral role for dendritic integration: HCN1 channels constrain spatial memory and plasticity at inputs to distal dendrites of CA1 pyramidal neurons. Cell119:719–32.
97.
NomuraDKMorrisonBEBlankmanJLLongJZKinseySGMarcondesMC, and others. 2011. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science334:809–13.
98.
Ohno-ShosakuTTsubokawaHMizushimaIYonedaNZimmerAKanoM. 2002. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J Neurosci22:3864–72.
99.
Ohno-ShosakuTTanimuraAHashimotodaniYKanoM. 2012. Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist18:119–32.
100.
OmaluBIDeKoskySTMinsterRLKambohMIHamiltonRLWechtCH. 2005. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery57:128–34.
101.
O’SullivanSE. 2007. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol152:576–82.
102.
O’SullivanSEKendallDA. 2010. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology215:611–6.
103.
OtmakhovaNALeweyJAsricanBLismanJE. 2005. Inhibition of perforant path input to the CA1 region by serotonin and noradrenaline. J Neurophysiol94:1413–22.
104.
OtmakhovaNALismanJE. 1999. Dopamine selectively inhibits the direct cortical pathway to the CA1 hippocampal region. J Neurosci19:1437–45.
105.
OtmakhovaNALismanJE. 2000. Dopamine, serotonin, and noradrenaline strongly inhibit the direct perforant path-CA1 synaptic input, but have little effect on the Schaffer collateral input. Ann N Y Acad Sci911:462–4.
106.
PanBWangWLongJZSunDHillardCJCravattBF, and others. 2009. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther331:591–7.
107.
PanikashviliDSimeonidouCBen-ShabatSHanusLBreuerAMechoulamR, and others. 2001. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature413:527–31.
108.
PanikashviliDMechoulamRBeniSMAlexandrovichAShohamiE. 2005. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab25:477–84.
109.
PanikashviliDSheinNAMechoulamRTrembovlerVKohenRAlexandrovichA, and others. 2006. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis22:257–64.
110.
PertweeRGHowlettACAboodMEAlexanderSPDi MarzoVElphickMR, and others. 2010. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev62:588–631.
111.
PiroJRBenjaminDIDuerrJMPiYGonzalesCWoodKM, and others. 2012. A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer’s disease. Cell Rep1:617–23.
112.
PisaniAFezzaFGalatiSBattistaNNapolitanoSFinazzi-AgròA, and others. 2005. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson’s disease patients. Ann Neurol57:777–9.
113.
PisaniVMoschellaVBariMFezzaFGalatiSBernardiG, and others. 2010. Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson’s disease patients. Mov Disord25:920–4.
114.
PistisMMelisM. 2010. From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr Med Chem17:1450–67.
PitlerTAAlgerBE. 1994. Depolarization-induced suppression of GABAergic inhibition in rat hippocampal pyramidal cells: G protein involvement in a presynaptic mechanism. Neuron13:1447–55.
117.
RackeMKDrewPD. 2008. PPARs in neuroinflammation. PPAR Res2008:638356.
118.
RamirezBGBlazquezCGomez del PulgarTGuzmanMde CeballosML. 2005. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci25:1904–13.
119.
RemondesMSchumanEM. 2002. Direct cortical input modulates plasticity and spiking in CA1 pyramidal neurons. Nature416:736–40.
120.
RemondesMSchumanEM. 2004. Role for a cortical input to hippocampal area CA1 in the consolidation of a long-term memory. Nature431:699–703.
121.
RicoteMLiACWillsonTMKellyCJGlassCK. 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature391:79–82.
122.
RobbeDKopfMRemauryABockaertJManzoniOJ. 2002. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A99:8384–8.
123.
RockwellCESniderNTThompsonJTVanden HeuvelJPKaminskiNE. 2006. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol70:101–11.
124.
RonesiJLovingerDM. 2005. Induction of striatal long-term synaptic depression by moderate frequency activation of cortical afferents in rat. J Physiol562:245–56.
125.
SafoPKRegehrWG. 2005. Endocannabinoids control the induction of cerebellar LTD. Neuron48:647–59.
126.
SalmonJAHiggsGA. 1987. Prostaglandins and leukotrienes as inflammatory mediators. Br Med Bull43:285–96.
127.
SarneYMechoulamR. 2005. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord4:677–84.
128.
SatoTHanyuHHiraoKKanetakaHSakuraiHIwamotoT. 2011. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging32:1626–33.
129.
SauerbeckAGaoJReadnowerRLiuMPaulyJRBingG, and others. 2011. Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol227:128–35.
130.
ScotterELAboodMEGlassM. 2010. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol160:480–98.
131.
ShohamiECohen-YeshurunAMagidLAlgaliMMechoulamR. 2011. Endocannabinoids and traumatic brain injury. Br J Pharmacol163:1402–10.
132.
SjostromPJTurrigianoGGNelsonSB. 2003. Neocortical LTD via coincident activation of presynaptic NMDA and cannabinoid receptors. Neuron39:641–54.
133.
SmithDHJohnsonVEStewartW. 2013. Chronic neuropathologies of single and repetitive TBI: substrates of dementia?Nat Rev Neurol9:211–21.
134.
SolasMFrancisPTFrancoRRamirezMJ. 2013. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer’s disease patients. Neurobiol Aging34:805–8.
135.
StellaN. 2009. Endocannabinoid signaling in microglial cells. Neuropharmacol56(Suppl 1):244–53.
136.
StewardOScovilleSA. 1976. Cells of origin of entorhinal cortical afferents to the hippocampus and fascia dentata of the rat. J Comp Neurol169:347–70.
137.
StraikerAHuSSLongJZArnoldAWager-MillerJCravattBF, and others. 2009. Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. Mol Pharmacol76:1220–7.
138.
SugiuraTKobayashiYOkaSWakuK. 2002. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids66:173–92.
139.
SugiuraTKondoSSukagawaANakaneSShinodaAItohK, and others. 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun215:89–97.
140.
TchantchouFZhangY. 2013. Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury. J Neurotrauma30:1–15.
141.
TufekciKUMeuwissenRGencSGencK. 2012. Inflammation in Parkinson’s disease. Adv Protein Chem Struct Biol88:69–132.
142.
van der SteltMDi MarzoV. 2005. Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med7:37–50.
143.
van der SteltMFoxSHHillMCrossmanARPetrosinoSDi MarzoV, and others. 2005. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson’s disease. FASEB J19:1140–2.
144.
van der SteltMMazzolaCEspositoGMatiasIPetrosinoSDe FilippisD, and others. 2006. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci63:1410–24.
145.
WangJUedaN. 2009. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat89:112–9.
146.
WestlakeTMHowlettACBonnerTIMatsudaLAHerkenhamM. 1994. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neurosci63:637–52.
WilsonRINicollRA. 2002. Endocannabinoid signaling in the brain. Science296:678–82.
149.
WoodcockTMorganti-KossmannMC. 2013. The role of markers of inflammation in traumatic brain injury. Frontiers Neurol4:1–18.
150.
XuJYChenRZhangJChenC. 2010. Endocannabinoids differentially modulate synaptic plasticity in rat hippocampal CA1 pyramidal neurons. PLoS One5:e10306.
151.
XuJYZhangJChenC. 2012. Long-lasting potentiation of hippocampal synaptic transmission by direct cortical input is mediated via endocannabinoids. J Physiol590: 2305–15.
152.
YasudaHHuangYTsumotoT. 2008. Regulation of excitability and plasticity by endocannabinoids and PKA in developing hippocampus. Proc Natl Acad Sci U S A105:3106–11.
153.
YiJPadalinoDJChinLSMontenegroPCantuRC. 2013. Chronic traumatic encephalopathy. Curr Sports Med Rep12:28–32.
154.
YiJHParkSWBrooksNLangBTVemugantiR. 2008. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res. 1244:164–72.
155.
ZetterbergHSmithDHBlennowK. 2013. Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol9:201–10.
